ALK and non-small cell lung carcinoma: Considering similar pattern of drug sensitivity between ALK and LTK, and the rarity of patients harboring specific resistance mechanisms, basket-type trials of targeted therapy for patients with specific resistance mutations might be useful, for example for L1256F/L650F mutated ALK/LTK fusion-positive NSCLC to efficiently develop targeted therapy for rare fusion-positive NSCLC resistant to prior targeted therapies.